Key result
Pentaerythritol Tetranitrate significantly increased the Diastolic/Systolic Time Tension Index Ratio from 1.15 to 1.46 (p<0.05) and decreased the Double Product from 9813 to 8336 (p<0.01).
Why the study?
Does Pentaerythritol Tetranitrate improve indicators of cardiac work in patients of type II AHA classification?
Does Pentaerythritol Tetranitrate improve indicators of cardiac work in patients of type II AHA classification?
Absolute Event Rate: 1.46% vs 1.15%
p-value: p=<0.05
Pentaerythritol Tetranitrate (40 mg) significantly improves noninvasive hemodynamic indicators of myocardial work in patients with AHA type II classification.
Authors
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for pentaerythritol tetranitrate in AHA type II; randomized trials needed before clinical consideration.
Winsor et al. (1982) studied Type II AHA classification (n=10). Pentaerythritol Tetranitrate (Peritrate) vs. Baseline (pre-treatment) was evaluated on Diastolic Time Tension Index/Systolic Time Tension Index Ratio (p=<0.05). Pentaerythritol Tetranitrate significantly increased the Diastolic/Systolic Time Tension Index Ratio from 1.15 to 1.46 (p<0.05) and decreased the Double Product from 9813 to 8336 (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: